Cannasouth Limited, a biopharmaceutical company, researches and develops cannabinoid-based therapeutic products in New Zealand. More Details
+ 2 more risks
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Cannasouth's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBD's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CBD exceeded the NZ Pharmaceuticals industry which returned -23.3% over the past year.
Return vs Market: CBD exceeded the NZ Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is Cannasouth's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDon't Ignore The Fact That This Insider Just Sold Some Shares In Cannasouth Limited (NZSE:CBD)
1 month ago | Simply Wall StHave Insiders Been Selling Cannasouth Limited (NZSE:CBD) Shares This Year?
4 months ago | Simply Wall StDo Insiders Own Shares In Cannasouth Limited (NZSE:CBD)?
Is Cannasouth undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CBD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CBD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CBD is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: CBD is unprofitable, so we can't compare its PE Ratio to the NZ market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CBD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CBD is overvalued based on its PB Ratio (6x) compared to the XO Pharmaceuticals industry average (3.9x).
How is Cannasouth forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannasouth has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Cannasouth's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Cannasouth competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Cannasouth performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CBD is currently unprofitable.
Growing Profit Margin: CBD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CBD's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CBD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (117.8%).
Return on Equity
High ROE: CBD has a negative Return on Equity (-17.75%), as it is currently unprofitable.
How is Cannasouth's financial position?
Financial Position Analysis
Short Term Liabilities: CBD's short term assets (NZ$13.4M) exceed its short term liabilities (NZ$465.9K).
Long Term Liabilities: CBD's short term assets (NZ$13.4M) exceed its long term liabilities (NZ$137.5K).
Debt to Equity History and Analysis
Debt Level: CBD is debt free.
Reducing Debt: CBD had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBD has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CBD has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 47.4% each year
What is Cannasouth current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBD's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Mark John Lucas serves as Chief Executive Officer of Cannasouth Limited and serves as its Executive Director since August 21, 2018. He is an experienced business manager who designs and implements oper ...
|CEO & Executive Director||no data||NZ$104.35k||23.08% |
|Independent Non-Executive Chairman||2.08yrs||NZ$58.57k||0.24% |
|Independent Non-Executive Director||2yrs||NZ$45.33k||0.0039% |
Experienced Board: CBD's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CBD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.
Cannasouth Limited's company bio, employee growth, exchange listings and data sources
- Name: Cannasouth Limited
- Ticker: CBD
- Exchange: NZSE
- Founded: 2018
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NZ$94.963m
- Shares outstanding: 121.75m
- Website: https://www.cannasouth.co.nz
- Cannasouth Limited
- 240 Victoria Street
- Floor 1
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CBD||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Jun 2019|
Cannasouth Limited, a biopharmaceutical company, researches and develops cannabinoid-based therapeutic products in New Zealand. Cannasouth Limited was incorporated in 2018 and is based in Hamilton, New Zea ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/29 10:44|
|End of Day Share Price||2020/10/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.